Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Business, Policy & Funding » Regulatory News & FDA Approvals » Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

Cepheid Receives CE Mark for SARS-CoV-2, Flu A/B, RSV Combination Test

Nov 24, 2020
|
staff reporter

NEW YORK ─ Sunnyvale, California-based Cepheid on Tuesday announced it has obtained CE-IVD marking for its Xpert Xpress SARS-CoV-2/Flu/RSV rapid molecular diagnostic test to detect from a single patient sample the viruses that cause COVID-19, Flu A, Flu B, and RSV infections.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Scan

Should Also Work

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

Worries About Increased Deadliness

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

Merck Stops SARS-CoV-2 Vaccine Development

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

PLOS Papers on Rare Venous Thromboembolism Variant, Vector Mosquito LncRNAs, More

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.

What's Popular?

In Regulatory News & FDA Approvals

  1. Fluidigm Obtains CE Mark for Saliva-Based SARS-CoV-2 Assay

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.